176 related articles for article (PubMed ID: 7591958)
1. Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism.
Ohashi M; Sugikawa E; Nakanishi N
Jpn J Cancer Res; 1995 Sep; 86(9):819-27. PubMed ID: 7591958
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine.
Sugikawa E; Hosoi T; Yazaki N; Gamanuma M; Nakanishi N; Ohashi M
Anticancer Res; 1999; 19(4B):3099-108. PubMed ID: 10652599
[TBL] [Abstract][Full Text] [Related]
3. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
David-Pfeuty T
Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500
[TBL] [Abstract][Full Text] [Related]
4. Cdk2/cdc2 expression in colon carcinogenesis and effects of cdk2/cdc2 inhibitor in colon cancer cells.
Yamamoto H; Monden T; Miyoshi H; Izawa H; Ikeda K; Tsujie M; Ohnishi T; Sekimoto M; Tomita N; Monden M
Int J Oncol; 1998 Aug; 13(2):233-9. PubMed ID: 9664116
[TBL] [Abstract][Full Text] [Related]
5. 9-hydroxyellipticine and derivatives as chemotherapy agents.
Harding MM; Grummitt AR
Mini Rev Med Chem; 2003 Mar; 3(2):67-76. PubMed ID: 12570841
[TBL] [Abstract][Full Text] [Related]
6. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells.
Lane ME; Yu B; Rice A; Lipson KE; Liang C; Sun L; Tang C; McMahon G; Pestell RG; Wadler S
Cancer Res; 2001 Aug; 61(16):6170-7. PubMed ID: 11507069
[TBL] [Abstract][Full Text] [Related]
7. 9-Hydroxyellipticine alters the conformation and DNA binding characteristics of mutated p53 protein.
Sugikawa E; Tsunoda S; Nakanishi N; Ohashi M
Anticancer Res; 2001; 21(4A):2671-5. PubMed ID: 11724337
[TBL] [Abstract][Full Text] [Related]
8. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382.
Ljungman M; Paulsen MT
Mol Pharmacol; 2001 Oct; 60(4):785-9. PubMed ID: 11562441
[TBL] [Abstract][Full Text] [Related]
9. The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A.
Luciani MG; Hutchins JR; Zheleva D; Hupp TR
J Mol Biol; 2000 Jul; 300(3):503-18. PubMed ID: 10884347
[TBL] [Abstract][Full Text] [Related]
10. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
11. Doenjang hexane fraction-induced G1 arrest is associated with the inhibition of pRB phosphorylation and induction of Cdk inhibitor p21 in human breast carcinoma MCF-7 cells.
Choi YH; Choi BT; Lee WH; Rhee SH; Park KY
Oncol Rep; 2001; 8(5):1091-6. PubMed ID: 11496322
[TBL] [Abstract][Full Text] [Related]
12. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells.
Akiyama T; Yoshida T; Tsujita T; Shimizu M; Mizukami T; Okabe M; Akinaga S
Cancer Res; 1997 Apr; 57(8):1495-501. PubMed ID: 9108451
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
14. p53-independent increase in p21WAF1 and reciprocal down-regulation of cyclin A and proliferating cell nuclear antigen in bromodeoxyuridine-mediated growth arrest of human melanoma cells.
Strasberg Rieber M; Welch DR; Miele ME; Rieber M
Cell Growth Differ; 1996 Feb; 7(2):197-202. PubMed ID: 8822203
[TBL] [Abstract][Full Text] [Related]
15. Caspase-mediated Cdk2 activation is a critical step to execute transforming growth factor-beta1-induced apoptosis in human gastric cancer cells.
Kim SG; Kim SN; Jong HS; Kim NK; Hong SH; Kim SJ; Bang YJ
Oncogene; 2001 Mar; 20(10):1254-65. PubMed ID: 11313870
[TBL] [Abstract][Full Text] [Related]
16. Regulation of CAK kinase activity by p53.
Schneider E; Montenarh M; Wagner P
Oncogene; 1998 Nov; 17(21):2733-41. PubMed ID: 9840937
[TBL] [Abstract][Full Text] [Related]
17. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53.
Bacus SS; Gudkov AV; Lowe M; Lyass L; Yung Y; Komarov AP; Keyomarsi K; Yarden Y; Seger R
Oncogene; 2001 Jan; 20(2):147-55. PubMed ID: 11313944
[TBL] [Abstract][Full Text] [Related]
18. p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells.
Choi YH; Lee WH; Park KY; Zhang L
Jpn J Cancer Res; 2000 Feb; 91(2):164-73. PubMed ID: 10761703
[TBL] [Abstract][Full Text] [Related]
19. G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation.
Akiyama T; Sugiyama K; Shimizu M; Tamaoki T; Akinaga S
Jpn J Cancer Res; 1999 Dec; 90(12):1364-72. PubMed ID: 10665655
[TBL] [Abstract][Full Text] [Related]
20. CSF-1 activates MAPK-dependent and p53-independent pathways to induce growth arrest of hormone-dependent human breast cancer cells.
Lee AW; Nambirajan S; Moffat JG
Oncogene; 1999 Dec; 18(52):7477-94. PubMed ID: 10602507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
